AIMD
Ainos·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 2
Bearish signal 2
Bearish Engulfing
Ample Liquidity
High Gross Profit Margin
Significant Revenue Decline
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About AIMD
Ainos, Inc.
A healthcare company, engages in the developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications
8880 Rio San Diego Drive, Ste. 800, San Diego, CA 92108
--
Ainos, Inc., a Texas corporation, was founded on June 26, 1984. Ainos is a diversified medical technology company focused on the development of novel point-of-care tests (POCT), low-dose interferon therapy and synthetic RNA (SRNA) to drive preventive medicine. Since its inception, the company has focused on research into low-dose non-injectable interferon therapies. The company recently expanded its product candidates to POCT to diversify the company's revenue streams. The POCT device is based on the core technology involved in the COVID 19 POCT product and other POCT products that detect volatile organic compounds (VOCs) released by the human body.
Company Financials
EPS
AIMD has released its 2025 Q3 earnings. EPS was reported at -0.64, versus the expected 0, missing expectations. The chart below visualizes how AIMD has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
AIMD has released its 2025 Q3 earnings report, with revenue of 2.17K, reflecting a YoY change of NaN%, and net profit of -2.93M, showing a YoY change of 20.75%. The Sankey diagram below clearly presents AIMD's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
